BusinessStrongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna ZentarisBy Nasdaq OMXJan 17, 2018, 12:00 PM UTC
BusinessStrongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s SyndromeBy Nasdaq OMXJun 27, 2017, 11:30 AM UTC
BusinessXOMA to Host XOMA 358 Clinical Update Webcast and Conference Call on September 15, 2016By Nasdaq OMXSep 6, 2016, 1:00 PM UTC
BusinessXOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO MeetingBy Nasdaq OMXApr 4, 2016, 1:00 PM UTC
